◎ Sugi Atlas

Atlas / Disease / Breast adenocarcinoma

Breast adenocarcinoma

disease
On this page

Also known as adenocarcinoma of breastadenocarcinoma of the breastmammary adenocarcinoma

Summary

Breast adenocarcinoma (MONDO:0004988) is a disease (an umbrella term covering 13 Mondo subtypes) with 6 cohort genes and 63 clinical trials. The dominant Reactome pathway is FLT3 Signaling (3 cohort genes). Molecularly, TP53 R175H is associated with resistance to MDM2 Inhibitor AMGMDS3 in Breast Adenocarcinoma (CIViC Level D). Top therapeutic interventions include goserelin, loperamide, and eribulin mesylate.

At a glance

  • Umbrella term: 13 Mondo subtypes
  • Cohort genes: 6
  • ClinVar variants: 11
  • Clinical trials: 63
  • Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namebreast adenocarcinoma
Mondo IDMONDO:0004988
EFOEFO:0000304
DOIDDOID:3458
NCITC5214
UMLSC0858252
MedGen167809
Anatomy (UBERON)UBERON:0000310, UBERON:0001911
Is cancer (heuristic)no

Also known as: adenocarcinoma of breast · adenocarcinoma of the breast · breast adenocarcinoma · mammary adenocarcinoma

Data availability: 11 ClinVar variants · 197 cell lines.

Disease family

An umbrella term covering 13 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › breast adenocarcinoma

Related subtypes (6): bartholin gland carcinoma, skin cancer, nipple carcinoma, atypical lobular breast hyperplasia, breast diffuse large B-cell lymphoma, dermatofibrosarcoma protuberans

Subtypes (13): breast lobular carcinoma, mammary Paget disease, signet ring cell breast carcinoma, breast mucinous cystadenocarcinoma, mucoepidermoid breast carcinoma, adenoid cystic breast carcinoma, sebaceous breast carcinoma, oncocytic breast carcinoma, breast malignant eccrine spiradenoma, breast ductal adenocarcinoma, lobular breast carcinoma in situ, mixed lobular and ductal breast carcinoma, inflammatory breast carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

11 retrieved; paginated sample, class counts are floors:

7 pathogenic, 3 pathogenic/likely pathogenic, 1 likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
13983NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys)AKT1Pathogeniccriteria provided, multiple submitters, no conflicts
12580NM_004985.5(KRAS):c.38G>A (p.Gly13Asp)KRASPathogeniccriteria provided, multiple submitters, no conflicts
13652NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)PIK3CAPathogenicreviewed by expert panel
13653NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)PIK3CAPathogeniccriteria provided, multiple submitters, no conflicts
13655NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)PIK3CAPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
3976NC_000008.11:g.52623770_52685461delRB1CC1Pathogenicno assertion criteria provided
3977nsv1067861RB1CC1Pathogenicno assertion criteria provided
6976NM_002555.6(SLC22A18):c.864_865ins[NC_000011.10:g.2919738_2919848]SLC22A18Pathogenicno assertion criteria provided
12369NM_000546.6(TP53):c.451C>A (p.Pro151Thr)TP53Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
12370NM_000546.6(TP53):c.451C>T (p.Pro151Ser)TP53Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
13654NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu)PIK3CALikely pathogeniccriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 51 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
TP53Orphanet:1333Familial pancreatic carcinoma
TP53Orphanet:145Hereditary breast and/or ovarian cancer syndrome
TP53Orphanet:1501Adrenocortical carcinoma
TP53Orphanet:210159Adult hepatocellular carcinoma
TP53Orphanet:251576Gliosarcoma
TP53Orphanet:251579Giant cell glioblastoma
TP53Orphanet:251899Choroid plexus carcinoma
TP53Orphanet:2807Papilloma of choroid plexus
TP53Orphanet:293199Pleomorphic rhabdomyosarcoma
TP53Orphanet:3318Essential thrombocythemia
TP53Orphanet:524Li-Fraumeni syndrome
TP53Orphanet:52688Myelodysplastic syndrome
TP53Orphanet:585909B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
TP53Orphanet:667662Breast implant-associated anaplastic large cell lymphoma
TP53Orphanet:668Osteosarcoma
TP53Orphanet:67038B-cell chronic lymphocytic leukemia
TP53Orphanet:70573Small cell lung cancer
TP53Orphanet:96253Cushing disease
TP53Orphanet:99756Alveolar rhabdomyosarcoma
TP53Orphanet:99757Embryonal rhabdomyosarcoma
SLC67A1Orphanet:227535Hereditary breast cancer
SLC67A1Orphanet:99757Embryonal rhabdomyosarcoma
AKT1Orphanet:201Cowden syndrome
AKT1Orphanet:2495Meningioma
AKT1Orphanet:744Proteus syndrome
KRASOrphanet:1333Familial pancreatic carcinoma
KRASOrphanet:1340Cardiofaciocutaneous syndrome
KRASOrphanet:144Lynch syndrome
KRASOrphanet:146Differentiated thyroid carcinoma
KRASOrphanet:2396Encephalocraniocutaneous lipomatosis
KRASOrphanet:251615Pilomyxoid astrocytoma
KRASOrphanet:2612Linear nevus sebaceus syndrome
KRASOrphanet:268114RAS-associated autoimmune leukoproliferative disease
KRASOrphanet:3339Oculoectodermal syndrome
KRASOrphanet:648Noonan syndrome
KRASOrphanet:86834Juvenile myelomonocytic leukemia
PIK3CAOrphanet:140944CLOVES syndrome
PIK3CAOrphanet:144Lynch syndrome
PIK3CAOrphanet:168984CLAPO syndrome
PIK3CAOrphanet:201Cowden syndrome
PIK3CAOrphanet:210159Adult hepatocellular carcinoma
PIK3CAOrphanet:221061Familial cerebral cavernous malformation
PIK3CAOrphanet:2495Meningioma
PIK3CAOrphanet:276280Hemihyperplasia-multiple lipomatosis syndrome
PIK3CAOrphanet:295239Macrodactyly of fingers, unilateral
PIK3CAOrphanet:295243Macrodactyly of toes, unilateral
PIK3CAOrphanet:314662Segmental progressive overgrowth syndrome with fibroadipose hyperplasia
PIK3CAOrphanet:60040Megalencephaly-capillary malformation-polymicrogyria syndrome
PIK3CAOrphanet:714737Diffuse capillary malformation with overgrowth
PIK3CAOrphanet:90308Capillary-lymphatic-venous malformation with segmental distribution

Cohort genes → proteins

6 cohort genes, 6 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence6

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
TP53HGNC:11998ENSG00000141510P04637Cellular tumor antigen p53clinvar,civic_evidence
SLC67A1HGNC:10964ENSG00000110628Q96BI1Solute carrier family 67 member A1clinvar
RB1CC1HGNC:15574ENSG00000023287Q8TDY2RB1-inducible coiled-coil protein 1clinvar
AKT1HGNC:391ENSG00000142208P31749RAC-alpha serine/threonine-protein kinaseclinvar
KRASHGNC:6407ENSG00000133703P01116GTPase KRasclinvar
PIK3CAHGNC:8975ENSG00000121879P42336Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformclinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
TP53Cellular tumor antigen p53Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence.
SLC67A1Solute carrier family 67 member A1May act as a transporter of organic cations based on a proton efflux antiport mechanism.
RB1CC1RB1-inducible coiled-coil protein 1Involved in autophagy.
AKT1RAC-alpha serine/threonine-protein kinaseAKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis.
KRASGTPase KRasRas proteins bind GDP/GTP and possess intrinsic GTPase activity.
PIK3CAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformPhosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides.

Protein-family classification

Druggable: 4 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.67

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Kinase29.2×0.088
Transporter113.0×0.187
Enzyme (other)12.0×0.674
Transcription factor11.4×0.674
Other/Unknown10.3×0.993

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
TP53Transcription factornop53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn
SLC67A1TransporteryesTet-R_TetA/multi-R_MdtG-like, MFS, MFS_dom
RB1CC1Other/UnknownnoAtg11_C, ATG11
AKT1Kinaseyes2.7.11.1Prot_kinase_dom, AGC-kinase_C, PH_domain
KRASEnzyme (other)yes3.6.5.2Small_GTPase, Small_GTP-bd, Small_GTPase_Ras-type
PIK3CAKinaseyes2.7.1.137PI3K_Ras-bd_dom, PI3/4_kinase_cat_dom, PI3K_accessory_dom

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)6
unknown0

Top tissues across cohort

TissueCohort genes
ganglionic eminence2
tendon of biceps brachii1
ventricular zone1
duodenum1
mucosa of transverse colon1
right lobe of liver1
bronchial epithelial cell1
buccal mucosa cell1
caput epididymis1
endometrium epithelium1
stromal cell of endometrium1
nipple1
pylorus1
trigeminal ganglion1
adrenal tissue1
calcaneal tendon1
tendon1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
TP53223ubiquitousmarkerventricular zone, ganglionic eminence, tendon of biceps brachii
SLC67A1132ubiquitousmarkermucosa of transverse colon, duodenum, right lobe of liver
RB1CC1296ubiquitousmarkerbuccal mucosa cell, bronchial epithelial cell, caput epididymis
AKT1273ubiquitousmarkerstromal cell of endometrium, ganglionic eminence, endometrium epithelium
KRAS298ubiquitousmarkertrigeminal ganglion, pylorus, nipple
PIK3CA284ubiquitousmarkercalcaneal tendon, adrenal tissue, tendon

Protein interactions among cohort

Intra-cohort edges: 4.

Hub genes (top 10 by interactor count)

SymbolInteractor count
TP5322,736
AKT116,601
KRAS14,509
PIK3CA5,157
RB1CC13,031
SLC67A11,306

Intra-cohort edges

ABSources
AKT1PIK3CAbiogrid_interaction, string_interaction
KRASPIK3CAstring_interaction
KRASTP53string_interaction
RB1CC1TP53string_interaction

Structural data

PDB: 5 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
KRASP01116511
TP53P04637313
PIK3CAP42336135
AKT1P3174943
RB1CC1Q8TDY218

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
SLC67A1Q96BI186.91

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 266. Enrichment computed across 6 evidence-associated genes (6 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
FLT3 Signaling3173.0×1e-04AKT1, KRAS, PIK3CA
Signaling by FGFR4 in disease2317.2×0.001KRAS, PIK3CA
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants2292.8×0.001KRAS, PIK3CA
Signaling by PDGFRA extracellular domain mutants2292.8×0.001KRAS, PIK3CA
Regulation of TP53 Activity through Association with Co-factors2271.9×0.001TP53, AKT1
Signaling by FLT3 ITD and TKD mutants2253.8×0.001KRAS, PIK3CA
Constitutive Signaling by EGFRvIII2237.9×0.001KRAS, PIK3CA
Signaling by ERBB2 ECD mutants2223.9×0.001KRAS, PIK3CA
Tie2 Signaling2200.3×0.001KRAS, PIK3CA
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants2190.3×0.001KRAS, PIK3CA
Signaling by FLT3 fusion proteins2190.3×0.001KRAS, PIK3CA
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants2173.0×0.001KRAS, PIK3CA
Signaling by FGFR3 in disease2165.5×0.001KRAS, PIK3CA
Regulation of TP53 Activity through Acetylation2152.3×0.001TP53, AKT1
Signaling by ERBB2 KD Mutants2141.0×0.001KRAS, PIK3CA
CD28 dependent PI3K/Akt signaling2131.3×0.002AKT1, PIK3CA
Downstream signal transduction2126.9×0.002KRAS, PIK3CA
DAP12 signaling2122.8×0.002KRAS, PIK3CA
Signaling by CSF1 (M-CSF) in myeloid cells2115.3×0.002KRAS, PIK3CA
Signaling by FGFR1 in disease297.6×0.002KRAS, PIK3CA
Regulation of TP53 Degradation297.6×0.002TP53, AKT1
Signaling by FGFR2 in disease288.5×0.002KRAS, PIK3CA
Signaling by SCF-KIT282.8×0.003KRAS, PIK3CA
Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1)11903.3×0.005SLC67A1
Loss of function of TP53 in cancer due to loss of tetramerization ability11903.3×0.005TP53
Extra-nuclear estrogen signaling256.8×0.005AKT1, PIK3CA
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells253.6×0.006AKT1, PIK3CA
Signaling by ALK fusions and activated point mutants250.1×0.006TP53, PIK3CA
VEGFA-VEGFR2 Pathway246.4×0.007AKT1, PIK3CA
TP53 Regulates Metabolic Genes243.3×0.008TP53, AKT1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
liver development3110.9×6e-04RB1CC1, KRAS, PIK3CA
anoikis2432.1×9e-04AKT1, PIK3CA
positive regulation of cellular senescence2432.1×9e-04TP53, KRAS
negative regulation of macroautophagy2374.5×9e-04AKT1, PIK3CA
striated muscle cell differentiation2330.4×9e-04AKT1, KRAS
glial cell proliferation2295.6×1e-03TP53, KRAS
negative regulation of proteolysis2224.7×0.001TP53, AKT1
insulin-like growth factor receptor signaling pathway2165.2×0.002AKT1, PIK3CA
response to muscle inactivity12808.7×0.004PIK3CA
mammalian oogenesis stage12808.7×0.004AKT1
positive regulation of endodeoxyribonuclease activity12808.7×0.004AKT1
negative regulation of helicase activity12808.7×0.004TP53
response to mineralocorticoid12808.7×0.004KRAS
cellular response to actinomycin D12808.7×0.004TP53
regulation of tRNA methylation12808.7×0.004AKT1
regulation of intrinsic apoptotic signaling pathway by p53 class mediator12808.7×0.004TP53
negative regulation of protein maturation12808.7×0.004AKT1
negative regulation of G1 to G0 transition12808.7×0.004TP53
response to butyrate12808.7×0.004PIK3CA
positive regulation of smooth muscle cell proliferation2110.1×0.004AKT1, PIK3CA
glucose metabolic process285.1×0.004AKT1, PIK3CA
epidermal growth factor receptor signaling pathway282.6×0.004AKT1, PIK3CA
insulin receptor signaling pathway273.9×0.004AKT1, PIK3CA
phosphatidylinositol 3-kinase/protein kinase B signal transduction270.2×0.004AKT1, PIK3CA
Ras protein signal transduction268.5×0.004TP53, KRAS
positive regulation of gene expression319.4×0.004TP53, AKT1, KRAS
neuron apoptotic process261.7×0.005TP53, KRAS
cellular response to insulin stimulus256.7×0.006AKT1, PIK3CA
ribophagy11404.3×0.007RB1CC1
positive regulation of mitochondrial membrane permeability11404.3×0.007TP53

Therapeutics

Drug target analysis

Approved (phase 4): 4 · Phase ≥3: 4 · Phased (≥1): 4 · Undrugged: 2

Druggability breadth: 5 of 6 evidence-associated genes (83%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
TP53NITROFURANTOIN
AKT1CAPIVASERTIB
KRASVEMURAFENIB
PIK3CAIDELALISIB

Top cohort targets by molecule count

SymbolMoleculesMax phase
TP531964
PIK3CA674
AKT1304
KRAS114
SLC67A100
RB1CC100

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
NITROFURANTOIN4TP53
DIOSMIN4TP53
VERTEPORFIN4TP53
CANDESARTAN CILEXETIL4TP53
DIENESTROL4TP53
CLOTRIMAZOLE4TP53
COLCHICINE4TP53
NABUMETONE4TP53
SALMETEROL XINAFOATE4TP53
AMIODARONE HYDROCHLORIDE4TP53
FURAZOLIDONE4TP53
AMOXAPINE4TP53
RALOXIFENE HYDROCHLORIDE4TP53
NICARDIPINE HYDROCHLORIDE4TP53
SULCONAZOLE NITRATE4TP53
PYRITHIONE ZINC4TP53
LACTIC ACID4TP53
OXYMETHOLONE4TP53
CHLOROXINE4TP53
PROPIOLACTONE4TP53
CLOMIPRAMINE HYDROCHLORIDE4TP53
PHENYL AMINOSALICYLATE4TP53
THIORIDAZINE HYDROCHLORIDE4TP53
AMITRIPTYLINE HYDROCHLORIDE4TP53
ETHOPROPAZINE HYDROCHLORIDE4TP53
MECHLORETHAMINE HYDROCHLORIDE4TP53
ECONAZOLE NITRATE4TP53
TRIFLUPROMAZINE HYDROCHLORIDE4TP53
PROCHLORPERAZINE EDISYLATE4TP53
DEQUALINIUM CHLORIDE4TP53

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 3.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
PIK3CA2,034Binding:2009, ADMET:19, Toxicity:4, Functional:2
AKT11,942Binding:1900, Functional:34, ADMET:7, Toxicity:1
TP53869Binding:775, ADMET:83, Functional:10, Toxicity:1
KRAS861Binding:829, Functional:32
SLC67A11Binding:1

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
AKT12.7.11.1non-specific serine/threonine protein kinase
KRAS3.6.5.2small monomeric GTPase
PIK3CA2.7.1.137, 2.7.1.153, 2.7.11.1phosphatidylinositol 3-kinase, phosphatidylinositol-4,5-bisphosphate 3-kinase, non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
TP53869
AKT11,942
KRAS861
PIK3CA2,034

Pharmacogenomics

Cohort genes with a PharmGKB record: 6; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
NITROFURANTOIN4TP53
DIOSMIN4TP53
VERTEPORFIN4TP53
CANDESARTAN CILEXETIL4TP53
DIENESTROL4TP53
CLOTRIMAZOLE4TP53
COLCHICINE4TP53
NABUMETONE4TP53
SALMETEROL XINAFOATE4TP53
AMIODARONE HYDROCHLORIDE4TP53
FURAZOLIDONE4TP53
AMOXAPINE4TP53
RALOXIFENE HYDROCHLORIDE4TP53
NICARDIPINE HYDROCHLORIDE4TP53
SULCONAZOLE NITRATE4TP53
PYRITHIONE ZINC4TP53
LACTIC ACID4TP53
OXYMETHOLONE4TP53
CHLOROXINE4TP53
PROPIOLACTONE4TP53
CLOMIPRAMINE HYDROCHLORIDE4TP53
PHENYL AMINOSALICYLATE4TP53
THIORIDAZINE HYDROCHLORIDE4TP53
AMITRIPTYLINE HYDROCHLORIDE4TP53
ETHOPROPAZINE HYDROCHLORIDE4TP53
MECHLORETHAMINE HYDROCHLORIDE4TP53
ECONAZOLE NITRATE4TP53
TRIFLUPROMAZINE HYDROCHLORIDE4TP53
PROCHLORPERAZINE EDISYLATE4TP53
DEQUALINIUM CHLORIDE4TP53

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)4TP53, AKT1, KRAS, PIK3CA
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug1SLC67A1
EDifficult family or no structure, no drug1RB1CC1

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
SLC67A11—
RB1CC10—

Clinical trials & evidence

Clinical trials

Clinical trials: 63.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified23
PHASE211
PHASE111
PHASE39
PHASE1/PHASE27
PHASE41
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05183828PHASE4RECRUITINGEffect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
NCT00310180PHASE3ACTIVE_NOT_RECRUITINGHormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
NCT00433511PHASE3ACTIVE_NOT_RECRUITINGDoxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
NCT02115282PHASE3ACTIVE_NOT_RECRUITINGExemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
NCT02488967PHASE3ACTIVE_NOT_RECRUITINGDoxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT00005970PHASE3COMPLETEDDoxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00869206PHASE3COMPLETEDZoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
NCT02037529PHASE3SUSPENDEDEribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
NCT03199885PHASE3TERMINATEDTesting the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
NCT04300829PHASE3UNKNOWNCicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients
NCT01245712PHASE2ACTIVE_NOT_RECRUITINGRadiation Therapy in Treating Patients With Stage 0-II Breast Cancer
NCT01730833PHASE2ACTIVE_NOT_RECRUITINGPertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
NCT02957968PHASE2ACTIVE_NOT_RECRUITINGNeoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
NCT05269381PHASE1/PHASE2RECRUITINGPersonalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT05579366PHASE1/PHASE2RECRUITINGRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT06538389PHASE2RECRUITINGHigh Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
NCT06596018PHASE1/PHASE2RECRUITINGAssessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy
NCT06671262PHASE2RECRUITINGNeoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer
NCT01697293PHASE1/PHASE2TERMINATEDPTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
NCT02067741PHASE2TERMINATEDCR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
NCT02282345PHASE2COMPLETEDTalazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
NCT02530489PHASE2COMPLETEDNab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
NCT03094052PHASE2COMPLETEDIncidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
NCT03106415PHASE1/PHASE2COMPLETEDPembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT03250676PHASE1/PHASE2COMPLETEDTrial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
NCT03666819PHASE2WITHDRAWNCarbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
NCT04197687PHASE2UNKNOWNTPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT04789668PHASE1/PHASE2TERMINATEDBintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
NCT02453620PHASE1ACTIVE_NOT_RECRUITINGEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
NCT04150042PHASE1RECRUITINGSHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients’ Own Stem Cells
NCT04521764PHASE1RECRUITINGA Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
NCT06745804PHASE1RECRUITINGStudy of 68Ga-R10602
NCT07020117PHASE1RECRUITINGA Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT02824575PHASE1TERMINATEDRebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
NCT03432741PHASE1TERMINATEDDirect Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
NCT04139993PHASE1TERMINATEDRBX7455 Before Surgery for the Treatment of Operable Breast Cancer
NCT04481113PHASE1COMPLETEDAbemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
NCT04535323PHASE1COMPLETEDPlatelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer
NCT04756505PHASE1WITHDRAWNImmunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial
NCT04857697EARLY_PHASE1COMPLETEDEffects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
GOSERELIN43
LOPERAMIDE43
ERIBULIN MESYLATE42
EXEMESTANE42
LETROZOLE42
PERTUZUMAB42
TAMOXIFEN CITRATE42
ANASTROZOLE41
ATEZOLIZUMAB41
ATROPINE41
BELINOSTAT41
BINIMETINIB41
COPANLISIB HYDROCHLORIDE41
CROFELEMER41
DIPHENOXYLATE41
NERATINIB41
NIRAPARIB TOSYLATE MONOHYDRATE41
PACLITAXEL41
ROMIDEPSIN41
TALAZOPARIB41
TRASTUZUMAB41
TRASTUZUMAB EMTANSINE41
BINTRAFUSP ALFA32
ENTINOSTAT32
ZENIDOLOL22
AQUACOBALAMIN21
IMMUNOCYTOKINE NHS-IL1221
PIMASERTIB21
REBASTINIB21
TRICIRIBINE PHOSPHATE21

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.

Molecular subtypeTherapyEffectLevelCIViC
TP53 R175HMDM2 Inhibitor AMGMDS3ResistanceCIViC DEID4880

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 70

This page pulls from 70 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncintactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptuberonufeatureumlsuniprot